Cadrenal Therapeutics, Inc. Common Stock beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-1.16 | $-1.14 | +1.7% | Beat |
| Q12026 FY2026 | $-1.51 | $-1.04 | +31.1% | Beat |
| Q42025 FY2025 | $-1.17 | $-1.41 | -20.5% | Miss |
Back to CVKD overview · CVKD holders · CVKD KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.